Q2 EPS Forecast for Gyre Therapeutics Reduced by Analyst

Key Points

• HC Wainwright lowered its Q2 2026 EPS estimate for Gyre Therapeutics to ($0.08) per share, down from ($0.06), and also forecast losses for the rest of 2026 and FY2027.
• Other analysts have been cautious on GYRE, with recent ratings including a downgrade to strong sell and a current consensus rating of Hold with an average price target of $17.00.
• Gyre recently reported Q1 earnings of $0.04 per share, missing estimates, while revenue of $37.2 million came in slightly above expectations; CEO Ying Luo also sold 10,136 shares in a recent insider transaction.

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Free Report) - Research analysts at HC Wainwright reduced their Q2 2026 EPS estimates for shares of Gyre Therapeutics in a report issued on Thursday, May 7th. HC Wainwright analyst M. Keller now forecasts that the company will earn ($0.08) per share for the quarter, down from their prior estimate of ($0.06). The consensus estimate for Gyre Therapeutics' current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Gyre Therapeutics' Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.30) EPS and FY2027 earnings at ($0.20) EPS.

GYRE has been the subject of several other research reports. Zacks Research downgraded shares of Gyre Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Monday, March 16th. Wall Street Zen downgraded shares of Gyre Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, March 14th. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of Gyre Therapeutics in a research report on Thursday, January 22nd. Two analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $17.00.

Gyre Therapeutics Stock Performance

GYRE opened at $7.47 on Monday. The firm has a 50 day moving average price of $7.58 and a 200 day moving average price of $7.69. The company has a market cap of $724.52 million, a PE ratio of -82.99 and a beta of 2.03. Gyre Therapeutics has a 1 year low of $6.57 and a 1 year high of $11.78.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last posted its earnings results on Thursday, March 12th. The company reported $0.04 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.08 by ($0.04). The business had revenue of $37.20 million for the quarter, compared to analyst estimates of $36.30 million. Gyre Therapeutics had a positive return on equity of 3.14% and a negative net margin of 5.44%.

Hedge Funds Weigh In On Gyre Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its holdings in Gyre Therapeutics by 13.0% in the fourth quarter. Geode Capital Management LLC now owns 423,222 shares of the company's stock worth $2,989,000 after purchasing an additional 48,602 shares during the period. State Street Corp lifted its stake in Gyre Therapeutics by 10.7% in the fourth quarter. State Street Corp now owns 202,225 shares of the company's stock valued at $1,428,000 after buying an additional 19,472 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Gyre Therapeutics by 37.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company's stock valued at $1,194,000 after buying an additional 45,772 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in Gyre Therapeutics by 4.7% in the first quarter. Bank of New York Mellon Corp now owns 43,144 shares of the company's stock valued at $301,000 after buying an additional 1,941 shares during the last quarter. Finally, Millennium Management LLC bought a new stake in Gyre Therapeutics in the third quarter valued at $267,000. Institutional investors and hedge funds own 23.99% of the company's stock.

Insider Buying and Selling

In other Gyre Therapeutics news, CEO Ying Luo sold 10,136 shares of Gyre Therapeutics stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $8.04, for a total value of $81,493.44. Following the completion of the transaction, the chief executive officer owned 2,565,226 shares of the company's stock, valued at $20,624,417.04. The trade was a 0.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 10.00% of the stock is currently owned by corporate insiders.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company's proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre's preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer's disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.